Cowpox is
an infectious disease caused by the cowpox virus. The virus, part of the
orthopoxvirus family, is closely related to the vaccinia virus.
The virus is zoonotic, meaning that it is transferable between species,
such as from animal to human. The transferral of the disease was first observed
in dairymaids who touched the udders of infected cows and
consequently developed the signature pustules on their hands. Cowpox
is more commonly found in animals other than bovines, such as rodents. Cowpox
is similar to, but much milder than, the highly contagious and often deadly smallpox disease. Its
close resemblance to the mild form of smallpox and the observation that
dairymaids were immune from smallpox inspired the first smallpox
vaccine, created and administered by English physician Edward
Jenner.
The word “vaccination,”
coined by Jenner in 1796, is
derived from the Latin root vaccinus, meaning of or from the cow. Once
vaccinated, a patient develops antibodies that
make him/her immune to cowpox, but they also develop immunity to the smallpox virus, or Variola
virus. The cowpox vaccinations and later
incarnations proved so successful that in 1980, the World Health Organizationannounced that
smallpox was the first disease to be eradicated by vaccination efforts
worldwide. Other orthopox viruses
remain prevalent in certain communities and continue to infect humans, such as
the cowpox virus (CPXV) in Europe, vaccinia in Brazil, and monkeypox
virus in Central and West Africa.
Origin
Discovery
In the years
from 1770 to 1790, at least six people who had contact with a cow had
independently tested the possibility of using the cowpox vaccine as an
immunization for smallpox in humans. Amongst them were the English farmer Benjamin
Jesty, in Dorset in
1774 and the German teacher Peter
Plett in 1791. Jesty
inoculated his wife and two young sons with cowpox, in a successful effort to
immunize them to smallpox, an epidemic of which had arisen in their town. His patients
who had contracted and recovered from the similar but milder cowpox (mainly
milkmaids), seemed to be immune not only to further cases of cowpox, but also to
smallpox. By scratching the fluid from cowpox lesions into the skin of healthy
individuals, he was able to immunize those people against smallpox. Reportedly,
farmers and people working regularly with cattle and horses were often spared
during smallpox outbreaks. Investigations by the British
Army in 1790 showed that horse-mounted troops were
less infected by smallpox than infantry, due to probable exposure to the similar horse pox
virus (Variola equina). By the early
19th century, more than 100,000 people in Great Britain had been vaccinated.
The arm-to-arm method of transfer of the cowpox vaccine was also used to
distribute Jenner's vaccine throughout the Spanish Empire. Spanish king Charles
IV's daughter had been stricken with smallpox in 1798, and after she recovered,
he arranged for the rest of his family to be vaccinated. In 1803, the king,
convinced of the benefits of the vaccine, ordered his personal physician
Francis Xavier de Balmis, to deliver it to the Spanish dominions in North and
South America. To maintain the vaccine in an available state during the voyage,
the physician recruited 22 young boys who had never had cowpox or smallpox
before, aged three to nine years, from the orphanages of Spain. During the trip
across the Atlantic, de Balmis vaccinated the orphans in a living chain. Two
children were vaccinated immediately before departure, and when cowpox pustules
had appeared on their arms, material from these lesions was used to vaccinate
two more children.
Jesty did
not publicize his findings, and Jenner, who performed his first inoculation 22
years later and publicized his findings, assumed credit. It is said that Jenner
made this discovery by himself, possibly without knowing previous accounts 20
years earlier. Although Jesty may have been the first to discover it, Jenner
made vaccination widely accessible and has therefore been credited for its
invention.
Implementation
Naturally
occurring cases of cowpox were not common, but it was discovered that the
vaccine could be “carried” in humans and reproduced and disseminated
human-to-human. Jenner’s original vaccination used lymph from the cowpox
pustule on a milkmaid, and subsequent “arm-to-arm” vaccinations applied the
same principle. As this transfer of human fluids came with its own set of
complications, a safer manner of producing the vaccine was first introduced in
Italy, The new method used cows to manufacture the vaccine using a process
called “retrovaccination,” in which a heifer was inoculated with humanized
cowpox virus, and it was passed from calf to calf to produce massive quantities
efficiently and safely. This then lead to the next incarnation, “true animal
vaccine,” which used the same process but began with naturally-occurring cowpox
virus, and not the humanized form.
This method
of production proved to be lucrative and was taken advantage of by many entrepreneurs needing
only calves and seed lymph from an infected cow to manufacture crude versions
of the vaccine. W. F. Elgin of the National Vaccine Establishment presented his
slightly refined technique to the Conference of State and Provincial Boards of
Health of North America. A tuberculosis-free
calf, stomach shaved, would be bound to an operating table, where incisions
would be made on its lower body. Glycerinated lymph from a previously
inoculated calf was spread along the cuts. After a few days, the cuts would
have scabbed or crusted over. The crust was softened with sterilized water and
mixed with glycerin, which disinfected it, then stored hermetically-sealed in
capillary tubes for later use.
At some
point, the virus in use was no longer cowpox, but vaccinia. Scientists have not
determined exactly when the change or mutation occurred, but the effects of
vaccinia and cowpox virus as vaccine are nearly the same.
After
inoculation, vaccination using the cowpox virus became the primary defense
against smallpox. After infection by the cowpox virus, the body (usually) gains
the ability to recognize the similar smallpox virus from its antigens and
is able to fight the smallpox disease much more efficiently.
The cowpox
virus contains 186 thousand base pairs of DNA, which contains the information
for about 187 genes. This makes cowpox one of the most complicated viruses
known. Some 100 of these genes give instructions for key parts of the human
immune system, giving a clue as to why the closely related smallpox is so
lethal. The
vaccinia virus now used for smallpox vaccination is sufficiently different from
the cowpox virus found in the wild as to be considered a separate virus.
Prevention
Today, the
virus is found in Europe, mainly in the UK. Human cases are very rare (though
in 2010 a laboratory worker contracted cowpox.) and most
often contracted from domestic cats. Human infections usually remain localized
and self-limiting, but can become fatal in immunosuppressed patients.
The virus is not commonly found in cattle; the reservoir hosts for the virus
are woodland rodents, particularly voles. Domestic
cats contract the virus from these rodents. Symptoms in cats include lesions on
the face, neck, forelimbs, and paws, and, less commonly, upper respiratory
tract infections. Symptoms of infection with cowpox virus in humans are
localized, pustular lesions generally found on the hands and limited to the
site of introduction. The incubation period is 9 to 10 days. The virus is most
prevalent in late summer and autumn.
Immunity to
cowpox is gained when the smallpox vaccine is administered. Though the vaccine
now uses vaccinia virus, the poxviruses are similar enough that the body
becomes immune to both cow- and smallpox.
Source: https://en.wikipedia.org/wiki/Cowpox
No comments:
Post a Comment